Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study

BACKGROUND: Subcutaneous tocilizumab (TCZ SC) is approved globally for giant cell arteritis (GCA). This phase Ib study investigated the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of intravenous (IV) TCZ 6 and 7 mg/kg in patients with GCA. This study explored an IV dose resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Christophe, Brockwell, Laura, Giraudon, Mylène, Zucchetto, Mauro, Christ, Lisa, Bannert, Bettina, Daikeler, Thomas, Villiger, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166308/
https://www.ncbi.nlm.nih.gov/pubmed/35659282
http://dx.doi.org/10.1186/s13075-022-02815-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166308/
https://www.ncbi.nlm.nih.gov/pubmed/35659282
http://dx.doi.org/10.1186/s13075-022-02815-9

Ejemplares similares